Gritstone bio is a biotechnology company developing targeted immunotherapies for cancer and infectious disease. Co. discovers, develops, manufactures, and delivers cancer and infectious disease immunotherapy candidates by utilizing both of its vaccine vectors, self-amplifying mRNA and chimpanzee adenovirus. Co.'s oncology programs in clinical stage development are GRANITE, an individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. Co.'s programs in clinical stage development are: CORAL, a second generation COVID-19 vaccine program and an HIV therapeutic/cure vaccine candidate that Co. is collaborating on with Gilead Sciences, Inc. The GRTS average annual return since 2018 is shown above.
The Average Annual Return on the GRTS average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GRTS average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GRTS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free GRTS Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
